Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

OBJECTIVE: Checkpoint inhibitors (CPIs) are in widespread clinical use. Little is known about which patients are at risk for developing toxicity. It is essential being able to identify patients with higher risk of experiencing immune‐related adverse events (IRAEs) before initiation of CPI treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsson Ladjevardi, Cecilia, Koliadi, Anthoula, Rydén, Viktoria, Inan El‐Naggar, Ali, Digkas, Evangelos, Valachis, Antonios, Ullenhag, Gustav J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315811/
https://www.ncbi.nlm.nih.gov/pubmed/37132258
http://dx.doi.org/10.1002/cam4.6013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315811/
https://www.ncbi.nlm.nih.gov/pubmed/37132258
http://dx.doi.org/10.1002/cam4.6013

Ejemplares similares